Nektar Therapeutics UK

Latest clinical program signals indexed for Nektar Therapeutics UK.

1. NKTR-358, Sodium Chloride 0.9% solution — Phase 2

   Jun 8, 2026
   Clinical update →

2. Pegylated Irinotecan — Phase 2

   Jun 8, 2026
   Clinical update →

3. Pegylated Irinotecan — Phase 2

   Jun 8, 2026
   Clinical update →

4. Etirinotecan pegol — Phase 2

   Jun 8, 2026
   Clinical update →

5. Dose Escalation Doublet: Combination of NKTR-214 + nivolumab — Phase 2

   Jun 8, 2026
   Clinical update →

6. Bempegaldesleukin — Phase 2

   Jun 8, 2026
   Clinical update →

7. Bempegaldesleukin (NKTR-214) — Phase 1

   Jun 8, 2026
   Clinical update →

8. Bempegaldesleukin — Phase 3

   Jun 8, 2026
   Clinical update →

1. 2023-507456-69-00

   NKTR-358, Sodium Chloride 0.9% solution

   Phase 2 · active · small_molecule

   Atopic Dermatitis

   CTIS ↗
2. 2023-509981-39-00

   NKTR-358, Placebo

   Phase 2 · active · small_molecule

   Alopecia Areata

   CTIS ↗
3. NCT00123201

   Dronabinol MDI

   Phase 2 · completed · small_molecule

   Migraine With Aura

   CT.gov ↗
4. NCT00370565

   Inhaled Human Insulin

   Phase 3 · completed · small_molecule

   Diabetes Mellitus, Type 2

   CT.gov ↗
5. NCT00396578

   aerosolized vancomycin or gentamicin

   Phase 2 · completed · small_molecule

   Ventilator Associated Pneumonia

   CT.gov ↗
6. NCT00598975

   NKTR-102 100 mg/m2

   Phase 2 · completed · small_molecule

   Tumor

   CT.gov ↗
7. NCT00600119

   placebo

   Phase 2 · completed · small_molecule

   Opioid Induced Constipation (OIC)

   CT.gov ↗
8. NCT00802945

   NKTR-102

   Phase 2 · completed · small_molecule

   Tumor

   CT.gov ↗
9. NCT00806156

   NKTR-102 q14d

   Phase 2 · completed · small_molecule

   Tumor

   CT.gov ↗
10. NCT00856375

    NKTR-102

    Phase 2 · completed · small_molecule

    Colorectal Cancer

    CT.gov ↗
11. NCT01004445

    Amikacin (BAY41-6551)

    Phase 2 · completed · small_molecule

    Pneumonia

    CT.gov ↗
12. NCT01021436

    Amikacin inhalation solution (BAY41-6551)

    Phase 2 · completed · small_molecule

    Pneumonia

    CT.gov ↗
13. NCT01457118

    NKTR-102 145 mg/m2

    Phase 2 · completed · small_molecule

    Malignant Solid Tumor

    CT.gov ↗
14. NCT01492101

    NKTR-102

    Phase 3 · completed · small_molecule

    Locally Recurrent Breast Cancer

    CT.gov ↗
15. NCT01619839

    NKTR-181

    Phase 2 · completed · small_molecule

    Osteoarthritis of the Knee

    CT.gov ↗
16. NCT01663012

    Etirinotecan pegol

    Phase 2 · completed · small_molecule

    Anaplastic Astrocytomas

    CT.gov ↗
17. NCT01799993

    Amikacin Inhalation Solution (BAY41-6551)

    Phase 3 · completed · small_molecule

    Pneumonia, Bacterial

    CT.gov ↗
18. NCT01876446

    Pegylated Irinotecan

    Phase 2 · completed · small_molecule

    Recurrent Small Cell Lung Carcinoma

    CT.gov ↗
19. NCT01976143

    NKTR-102

    Phase 1 · completed · small_molecule

    Advanced Cancer

    CT.gov ↗
20. NCT01991678

    145 mg/m2 NKTR 102

    Phase 1 · completed · small_molecule

    Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

    CT.gov ↗
21. NCT02312622

    Pegylated Irinotecan

    Phase 2 · completed · small_molecule

    Stage IV Non-small Cell Lung Cancer (NSCLC)

    CT.gov ↗
22. NCT02362672

    NKTR-181 BID tablets

    Phase 3 · completed · small_molecule

    Low Back Pain

    CT.gov ↗
23. NCT02367820

    NKTR-181 BID tablets

    Phase 3 · completed · small_molecule

    Low Back Pain

    CT.gov ↗
24. NCT02869295

    NKTR-214

    Phase 2 · completed · small_molecule

    Unspecified Adult Solid Tumor, Protocol Specific

    CT.gov ↗
25. NCT02915744

    NKTR-102

    Phase 3 · completed · small_molecule

    Metastasis

    CT.gov ↗
26. NCT02983045

    Dose Escalation Doublet: Combination of NKTR-214 + nivolumab

    Phase 2 · completed · small_molecule

    Melanoma

    CT.gov ↗
27. NCT03138889

    NKTR-214

    Phase 2 · terminated · small_molecule

    Non-Small Cell Lung Cancer

    CT.gov ↗
28. NCT03435640

    NKTR-262

    Phase 2 · terminated · small_molecule

    Melanoma

    CT.gov ↗
29. NCT03548467

    VB10.NEO

    Phase 2 · completed · mab

    Locally Advanced or Metastatic Solid Tumours

    CT.gov ↗
30. NCT03556007

    LY3471851

    Phase 2 · completed · small_molecule

    Systemic Lupus Erythematosus

    CT.gov ↗
31. NCT03635983

    NKTR-214

    Phase 3 · completed · mab

    Melanoma

    CT.gov ↗
32. NCT03729245

    bempegaldesleukin

    Phase 3 · terminated · mab

    Renal Cell Carcinoma

    CT.gov ↗
33. NCT03745807

    NKTR-214

    Phase 1 · completed · mab

    Advanced Cancer

    CT.gov ↗
34. NCT03772288

    TAK-659

    Phase 1 · terminated · small_molecule

    Lymphoma, Non-Hodgkin

    CT.gov ↗
35. NCT03785925

    Bempegaldesleukin

    Phase 2 · completed · mab

    Urinary Bladder Neoplasm

    CT.gov ↗
36. NCT03802227

    NKTR-181

    Phase 1 · terminated · small_molecule

    Moderate to Severe Chronic Pain

    CT.gov ↗
37. NCT04052204

    avelumab

    Phase 2 · terminated · small_molecule

    Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    CT.gov ↗
38. NCT04081350

    LY3471851

    Phase 1 · completed · small_molecule

    Dermatitis, Atopic

    CT.gov ↗
39. NCT04119557

    Placebo

    Phase 1 · completed · small_molecule

    Psoriasis

    CT.gov ↗
40. NCT04133116

    LY3471851

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
41. NCT04136756

    NKTR-255

    Phase 1 · completed · small_molecule

    Multiple Myeloma

    CT.gov ↗
42. NCT04209114

    Nivolumab

    Phase 3 · completed · mab

    Bladder Cancer

    CT.gov ↗
43. NCT04380324

    LY3471851

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
44. NCT04410445

    Bempegaldesleukin

    Phase 3 · terminated · mab

    Melanoma

    CT.gov ↗
45. NCT04433585

    LY3471851

    Phase 2 · completed · small_molecule

    Systemic Lupus Erythematosus

    CT.gov ↗
46. NCT04540705

    Nivolumab

    Phase 1 · completed · mab

    Renal Cell Carcinoma

    CT.gov ↗
47. NCT04616196

    NKTR-255

    Phase 2 · completed · small_molecule

    Head and Neck Squamous Cell Carcinoma

    CT.gov ↗
48. NCT04646044

    Bempegaldesleukin

    Phase 1 · completed · small_molecule

    Covid-19

    CT.gov ↗
49. NCT04677179

    LY3471851

    Phase 2 · terminated · small_molecule

    Colitis, Ulcerative

    CT.gov ↗
50. NCT04730349

    Nivolumab

    Phase 2 · terminated · mab

    Ependymoma

    CT.gov ↗
51. NCT04936841

    NKTR-214

    Phase 2 · terminated · small_molecule

    Head and Neck Cancer

    CT.gov ↗
52. NCT04955262

    Bempegaldesleukin (NKTR-214)

    Phase 1 · terminated · mab

    Metastatic Melanoma

    CT.gov ↗
53. NCT04969861

    Bempegaldesleukin

    Phase 3 · terminated · small_molecule

    Metastatic Head and Neck Cancer

    CT.gov ↗
54. NCT04998487

    LY3471851

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
55. NCT05327530

    Avelumab

    Phase 2 · active · small_molecule

    Locally Advanced or Metastatic Urothelial Carcinoma

    CT.gov ↗
56. NCT05359211

    Cyclophosphamide

    Phase 1 · active · small_molecule

    Recurrent Diffuse Large B-Cell Lymphoma

    CT.gov ↗
57. NCT05565729

    LY3471851

    Phase 1 · completed · small_molecule

    Healthy

    CT.gov ↗
58. NCT05632809

    NKTR-255

    Phase 2 · active · small_molecule

    Lung Cancer

    CT.gov ↗
59. NCT05664217

    NKTR-255 at 1.5 µg/kg

    Phase 3 · terminated · small_molecule

    Non-Hodgkin Lymphoma

    CT.gov ↗
60. NCT05676749

    C-TIL051

    Phase 1 · terminated · mab

    Metastatic Non Small Cell Lung Cancer

    CT.gov ↗
61. NCT06136741

    Rezpegaldesleukin

    Phase 2 · active · small_molecule

    Moderate to Severe Atopic Dermatitis

    CT.gov ↗
62. NCT06340360

    Rezpegaldesleukin

    Phase 2 · active · small_molecule

    Alopecia Areata

    CT.gov ↗